Otsuka Holdings Co., Ltd.: Attention Deficit Disorder with Hyperactivity trials

The registry lists 24 Attention Deficit Disorder with Hyperactivity studies with Otsuka Holdings Co., Ltd. as lead sponsor. 5 are open to participants now and 8 have results posted.

Phase 1 7Phase 2 7Phase 3 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationRecruitingNCT07759154Phase 3
• A Long-term Trial of EB-1020 in Pediatric Patients With ADHDRecruitingNCT07087327Phase 3
• A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDRecruitingNCT07086313Phase 2/3
• Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsRecruitingNCT06931080Phase 2/3
• A Long-term Trial of EB-1020 in Adult Patients With ADHDRecruitingNCT06926829Phase 3
• Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)CompletedNCT04081363Phase 2Results posted
• A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity DisorderCompletedNCT03605849Phase 3Results posted
• A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity DisorderCompletedNCT03605836Phase 3Results posted
• A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity DisorderCompletedNCT03605680Phase 3Results posted
• The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity DisorderCompletedNCT03324581Phase 2Results posted
• Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)CompletedNCT02547428Phase 2Results posted
• Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity DisorderCompletedNCT01939353Phase 2Results posted
• Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderCompletedNCT01074294Phase 2Results posted
• Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy SubjectsCompletedNCT07486895Phase 1
• A Trial to Assess How Centanafadine Interacts With Stimulants in the BodyCompletedNCT07314333Phase 1
• A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood LevelsCompletedNCT07253441Phase 1
• P3b Short-term Study of CTN in Patients With ADHD and Comorbid AnxietyCompletedNCT06973577Phase 3
• A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)CompletedNCT05428033Phase 3
• A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.CompletedNCT05279313Phase 3
• A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity DisorderCompletedNCT05257265Phase 3
• A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity DisorderCompletedNCT04786730Phase 1
• A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity DisorderCompletedNCT04398225Phase 1
• A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy SubjectsTerminatedNCT02827513Phase 1
• A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant UsersCompletedNCT02144415Phase 1